About Mark Benjamin
Mark Benjamin is a president and EVP business development at Cyrus Biotechnology.
Mark Benjamin first appears on SEC filings in 2021.
Experience
This experience comes from Mark Benjamin's profile and from SEC filings. For roles taken from filings, the years are when the filings name Mark Benjamin in the role, so the role may have started earlier or lasted longer.
Cyrus Biotechnology, Inc. Current
President & EVP Business Development
2019 – Present · Seattle, WA
Develops protein-based drug candidates for its own pipeline and biotechnology and pharmaceutical partners.
ML
MBB Consulting LLC Current
Owner
2018 – Present
SG
Simcere Pharmaceutical Group
Advisor - Business Development
2019 – 2020
PH
Phosphorex
Advisor - Business Development
2018 – 2020
QB
Q-State Biosciences
Chief Business Officer
2016 – 2017
GC
Galenea Corp.
President & CEO | Board Member
2007 – 2016
NU
Nura
Chief Business Officer
2004 – 2006
UW
University of Washington
IRB Member and Chairman Pro-tem
2004 – 2006
MM
Manteia Predictive Medicine
President, US Operations | VP, Global Business Development | Board Member
2001 – 2003
RI
Rosetta Inpharmatics
Sr. Director, Business Development
1999 – 2001
XE
Xenometrix
VP Business Development
1992 – 1999
Key Colleagues at Startups
The people Mark Benjamin works with at each company, as listed on that company's latest Form D.
Cyrus Biotechnology, Inc. · Form D/A, May 8, 2026
CW
Chad Waite
Board Member
Yifan Song
Chief Technology Officer and director
JS
Jason Smith
Board Member
Lucas Nivon
Chief Executive Officer and director
AM
Anthony Manning
Board Member
RS
Ramakrishna Satyavolu
Director